The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials.
Por:
Cho K, Park S, Koyanagi A, Jacob L., Yon DK, Lee SW, Kim MS, Kim SU, Kim BK, Shin JI and Smith L
Publicada:
1 sep 2022
Ahead of Print:
18 may 2022
Resumen:
Nonalcoholic fatty liver disease (NAFLD) is a liver disease that affects approximately 25% of the world's population, and various treatments have been applied for NAFLD patients. We compared the effectiveness of each intervention conducted to treat NAFLD by evaluating meta-analyses of pharmacological interventions and lifestyle modification including diet and exercise. We searched Pubmed/Medline, Embase, and Cochrane Library and included meta-analyses of randomized controlled trials investigating the effects of pharmacological intervention and lifestyle modification on NAFLD. The quality of included meta-analyses was evaluated by AMSTAR-2. If the effect size was expressed as mean difference, it was converted to standardized mean difference based on the random-effects model. A total of 1694 meta-analyses were identified, and 27 meta-analyses were eventually included in the review. Regarding pharmacological interventions, there was a high strength of evidence for the ALT reduction effect of silymarin on inactive controls (SMD = 0.88, p < 0.01, seven trials, 518 participants). Meanwhile, it was confirmed that appropriate diet and exercise were important in reducing liver fat (SMD = 1.51, p < 0.01, 12 trials, 765 participants). This umbrella review assessed the effects of pharmacological interventions and lifestyle modifications in the treatment of NAFLD. The results of this review can be utilized for clinical decisions when treating NAFLD patients.
Filiaciones:
Cho K:
Yonsei University College of Medicine, Seoul, Republic of Korea
Park S:
Yonsei University College of Medicine, Seoul, Republic of Korea
Koyanagi A:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, 08830, Barcelona, Spain
ICREA, Barcelona, Spain
Jacob L.:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, 08830, Barcelona, Spain
Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France
Yon DK:
Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea
Lee SW:
Department of Data Science, Sejong University College of Software Convergence, Seoul, Republic of Korea
Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
Kim MS:
Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea
Kim SU:
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea
Kim BK:
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea
Shin JI:
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
Smith L:
Cambridge Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK
Green Accepted
|